No Record Found
Sector
PharmaceuticalsOpen
₹49.9Prev. Close
₹53.49Turnover(Lac.)
₹14.97Day's High
₹51.3Day's Low
₹49.552 Week's High
₹9052 Week's Low
₹48Book Value
₹15.77Face Value
₹10Mkt Cap (₹ Cr.)
311.74P/E
108.68EPS
0.47Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
Equity Capital  | 61.03  | 61.03  | 61.03  | 61.03  | 
Preference Capital  | 0  | 0  | 0  | 0  | 
Reserves  | 35.1  | 29.51  | 21.24  | 9.61  | 
Net Worth  | 96.13  | 90.54  | 82.27  | 70.64  | 
Minority Interest  | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Revenue  | 22.44  | 25.93  | 11.14  | 2.25  | 
yoy growth (%)  | -13.46  | 132.75  | 394.37  | 9.43  | 
Raw materials  | -0.03  | -0.5  | -0.79  | -1.66  | 
As % of sales  | 0.14  | 1.94  | 7.16  | 74.03  | 
Employee costs  | -6.49  | -5.76  | -5.06  | -3.02  | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Profit before tax  | -1.21  | 4.4  | -11.85  | -21.69  | 
Depreciation  | -6.45  | -4.84  | -3.9  | -3.87  | 
Tax paid  | 0  | 0  | 0  | 0  | 
Working capital  | 0.71  | -0.28  | 52.29  | -18.35  | 
Other operating items  | 
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Growth matrix (%)  | ||||
Revenue growth  | -13.46  | 132.75  | 394.37  | 9.43  | 
Op profit growth  | -28.29  | -213.09  | -24.38  | 35.6  | 
EBIT growth  | -93.72  | -156.37  | -33.78  | 22.48  | 
Net profit growth  | -111.27  | -190.94  | -40.35  | 3.82  | 
| Particulars (Rupees in Crores.) | Mar-2010 | Mar-2009 | Mar-2008 | Mar-2007 | Mar-2006 | 
|---|---|---|---|---|---|
Gross Sales  | 6.57  | 6.01  | 8.22  | 13.46  | 13.19  | 
Excise Duty  | 0  | 0  | 0  | 0.62  | 0.82  | 
Net Sales  | 6.57  | 6.01  | 8.22  | 12.82  | 12.36  | 
Other Operating Income  | 0  | 0  | 0  | 0  | 0  | 
Other Income  | 2.1  | 4.63  | 2.17  | 9.31  | 0.09  | 
Company Name  | LTP (₹)  | P/E  (%)  | Mkt.Cap  (₹Cr.)  | NP Qtr (₹Cr.)  | Div.Yield  (%)  | Sales Qtr  (₹.Cr)  | Book Value (₹)  | 
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA  | 1,707.25  | 82.24 | 4,09,626.46 | 753.53 | 0.94 | 5,566.68 | 101.44 | 
Divis Laboratories Ltd DIVISLAB  | 6,805.65  | 77.34 | 1,80,668.62 | 557 | 0.44 | 2,357 | 561.08 | 
Torrent Pharmaceuticals Ltd TORNTPHARM  | 3,628.15  | 61.77 | 1,22,787.57 | 551 | 0.17 | 2,567 | 224.34 | 
Cipla Ltd CIPLA  | 1,511.6  | 23.49 | 1,22,102.7 | 1,210.53 | 1.06 | 4,495.16 | 411.56 | 
Dr Reddys Laboratories Ltd DRREDDY  | 1,196.45  | 18.5 | 99,857.36 | 387.3 | 0.67 | 4,602.9 | 377.57 | 
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Jignesh Anantray Goradia
Chairman (Non-Executive)
Azadar Hussain Khan
Independent Director
Chintan Jitendra Shah
Company Sec. & Compli. Officer
Abdul Gafoor Mohammad
Independent Director
JAGRUTI PRASHANT SHETH
Non Executive Director
Rakeshchandra Jagdishprasad Sinha
Additional Director
Premal Hemant Gandhi
S No 250-252 Turkapally Villag,
Shameerpet Mandal RR District,
Telangana - 500078
Tel: 91-40-23480430/0435
Website: http://www.zenotechlab.com
Email: abdul.gafoor@zenotech.co.in
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Zenotech Laboratories Limited was initially established as Sunline Technologies Limited in June, 1989 and changed to the present name w.e.f. August 9, 2004. Company is a loan licensing company caterin...
Read More
Reports by Zenotech Laboratories Ltd
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.